Evidence map›Paper›PMID 33422359›Full record

ReviewTrends in cell biology2021

Mitochondrial DNA Dynamics in Reprogramming to Pluripotency.

Alexander J Sercel, Natasha M Carlson, Alexander N Patananan, Michael A Teitell

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. The role of lipids in genome integrity and pluripotency.Biochemical Society transactions · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Roles of Mitochondrial DNA Damage in Kidney Diseases: A New Biomarker.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alexander J SercelMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA 90095.
Natasha M CarlsonDepartment of Biology, California State University Northridge, CA, USA 91330; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA 90095.
Alexander N PatanananDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA 90095.
Michael A TeitellDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA 90095; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA 90095; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA 90095; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA 90095; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research University of California, Los Angeles, Los Angeles, CA, USA 90095; Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA 90095; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA 90095. Electronic address: mteitell@mednet.ucla.edu.
University of California, Los Angeles · USCalifornia State University, Northridge · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
RNA trafficking in mitochondriaR01GM073981 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Carla M Koehler, MICHAEL A TEITELL · 2006 to 2026
$5.1M
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and PrognosisR01CA185189 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, JASON C, TEITELL, MICHAEL A · 2014 to 2017
$1.9M
Reverse Mitochondrial Genetics Enabled by BlastR01GM114188 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2015 to 2018
$1.9M
SPOTs: Optical Technologies for Instantly Quantifying Multicellular Response ProfilesR01GM127985 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2020 to 2023
$1.7M
(PQ5) Mitochondrial Transfer in Tumor Heterogeneity and Acquired Resistence to TherapyR21CA227480 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2019 to 2020
$373k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA185189NCI NIH HHS R21 CA227480NCI NIH HHS T32 CA009120NIGMS NIH HHS R01 GM073981NIGMS NIH HHS R01 GM114188NIGMS NIH HHS R01 GM127985NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

Mammalian cells, with the exception of erythrocytes, harbor mitochondria, which are organelles that provide energy, intermediate metabolites, and additional activities to sustain cell viability, replication, and function. Mitochondria contain multiple copies of a circular genome called mitochondrial DNA (mtDNA), whose individual sequences are rarely identical (homoplasmy) because of inherited or sporadic mutations that result in multiple mtDNA genotypes (heteroplasmy). Here, we examine potential mechanisms for maintenance or shifts in heteroplasmy that occur in induced pluripotent stem cells (iPSCs) generated by cellular reprogramming, and further discuss manipulations that can alter heteroplasmy to impact stem and differentiated cell performance. This additional insight will assist in developing more robust iPSC-based models of disease and differentiated cell therapies.

Indexed as

DNA, MitochondrialInduced Pluripotent Stem CellsAnimalsCellular ReprogrammingMitochondriaMitochondrial DynamicsDNA, Mitochondrialheteroplasmyinduced pluripotent stem cellmitochondrial DNApluripotencyreprogramming

Identifiers

PMID33422359
PMCPMC7954944
OpenAlexW3119604146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.